Synopsis: What does it take to turn a once-fringe scientific idea into a new approach to drug discovery—and build a biotech company around it for the long haul? In this episode of Biotech 2050, host Rahul Chaturvedi sits down with Nello Mainolfi, Founder, President & CEO of Kymera Therapeutics, to explore his journey from chemist and drug hunter to biotech founder, and the decade-long evolution of Kymera into a leader in targeted protein degradation. Nello shares how scientific curiosity first drew him to protein degradation when the modality was barely known across the industry, why he believes biotech companies must “earn the right to grow,” and how Kymera made the pivotal decision to move away from oncology and concentrate its resources on immunology. He also discusses Kymera’s clinical progress, including its STAT6 and IRF5 degrader programs, and the potential for oral medicines to address pathways historically targeted by injectable biologics. Beyond the science, Nello offers lessons from his evolution as a first-time founder CEO—from hiring and retaining the right people to building trust, preserving culture as an organization scales, knowing when to go deep and when to delegate, and maintaining resilience amid the constant demands of leading a public biotech company. Tune in for a conversation about scientific conviction, disciplined company building, targeted protein degradation, and why people and culture can ultimately matter as much as the technology itself. Biography: Nello is Founder, President, and Chief Executive Officer of Kymera Therapeutics. Under his leadership, Kymera has advanced a novel modality and built a pipeline of multiple clinical stage, first-in-class degrader programs across a variety of indications; developed a best-in-class drug discovery platform; raised close to $3 billion in capital and formed strategic collaborations with major biopharmaceutical companies. Nello began his career at Novartis, leading cross-functional teams that identified several novel investigational medicines including the first-in-class, FDA approved, factor B inhibitor iptacopan. Nello studied at Imperial College, University of London and The Scripps Research Institute in California and has authored more than 100 publications and patents. He is passionate about helping teams achieve what has not been done before and scaling Kymera into a leading global biopharma company.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related